{"id":133712,"date":"2022-09-02T04:28:36","date_gmt":"2022-09-02T08:28:36","guid":{"rendered":"https:\/\/44.250.171.167\/?p=133712"},"modified":"2022-10-06T05:04:11","modified_gmt":"2022-10-06T09:04:11","slug":"aurobindo-pharma-limited-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Aurobindo Pharma Limited Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Aurobindo Pharma Limited Q1 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/b8g7f6BUs9Y?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Aurobindo Pharma Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/AUROPHARMA\/\">AUROPHARMA<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:08:34] Prakash Agarwal of Axis Capital asked about the price erosion trends. Ram Prasad Chairman replied that the company is seeing some kind of tapering and believes the price erosion in 1Q23 vs 4Q22 is 2% and with shelf stock adjustment it\u2019s closer to around 3%.<\/li>\n<\/ul>\n<ul>\n<li>[00:09:12] Prakash Agarwal of Axis Capital enquired about growth not picking up in injectibles. Yugandhar Puvvala CEO of Eugia Pharma answered that in US the growth was 16%. The overall growth is in single digit at the global level. The company added, it\u2019s confident of hitting double digit growth for FY23.<\/li>\n<\/ul>\n<ul>\n<li>[00:09:53] Prakash Agarwal of Axis Capital also asked about the update on company\u2019s outlook of doubling the business in next two years. Ram Prasad Chairman clarified that the company is still on track to hit the guidance for FY24 of $650-700 million.<\/li>\n<\/ul>\n<ul>\n<li>[00:10:41]\u00a0Prakash Agarwal of Axis Capital asked about gross margin and its outlook going forward. S. Subramanian CFO answered that it will be the same 3%. AUROPHARMA believe going forward it must be in this range in the coming quarter and probably there must be softening coming in 3Q.<\/li>\n<\/ul>\n<ul>\n<li>[00:11:59] Prakash Agarwal of Axis Capital also asked about EBITDA margin outlook. S. Subramanian CFO said that even though it look like low in 1Q23, the company had additional expenditure of around INR60 crores. Going forward that additional expense won\u2019t be there.<\/li>\n<\/ul>\n<ul>\n<li>[00:17:00] Shyam Srinivasan with Goldman Sachs asked about the Europe business update. S. Subramanian CFO answered that Europe business is stable and growing. In 1Q23 there was 6% growth and 4Q22 was 7% growth. The markets are about 0-3% growth. AUROPHARMA is expecting 5-8% growth YonY.<\/li>\n<\/ul>\n<ul>\n<li>[00:21:46] Praveen Kale asked about the stock price as it\u2019s not appreciating much as expected and what it means to retail investors. S. Subramanian CFO said the company cannot comment about share price, but in terms of performance, AUROPHARMA has given a clear roadmap of where it is heading.<\/li>\n<\/ul>\n<ul>\n<li>[00:34:31] Surya Patra of PhillipCapital asked about the status of the PLI Project. S. Subramanian CFO replied that the project has already started and the company expects to install the entire thing by about 2Q23 and then do the pilot batches etc. The completion is expected by 4Q24 and commissioning by April 1, 2024.<\/li>\n<\/ul>\n<ul>\n<li>[00:36:35] Nitin Agarwal from IDFC asked about the update on the China business. Ram Prasad Chairman answered that the plant was completed and the company has taken 11 exhibit batches and the filings will start from Oct. onwards. In 2024, AUROPHARMA expects commercials to start in China.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q1 FY23 Earnings Concall Q&amp;A Highlights: [00:08:34] Prakash Agarwal of Axis Capital asked about the price erosion trends. Ram Prasad Chairman replied that the company is seeing some kind of tapering and believes the price erosion in 1Q23 vs 4Q22 is 2% and with shelf stock adjustment it\u2019s [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Aurobindo Pharma Limited Q1 FY23 Earnings Conference Call Insights #AUROPHARMA #Q1 #FY23 #Earnings","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-133712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":131575,"url":"https:\/\/alphastreet.com\/india\/syngene-international-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133712,"position":0},"title":"Syngene International Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"July 22, 2022","format":false,"excerpt":"https:\/\/youtu.be\/xL_nlERmIDQ Key highlights from Syngene International Ltd (SYNGENE) Q1 FY23 Earnings Concall Q&A Highlights: Prakash Agarwal from Axis Capital asked about the constant currency growth seen in 1Q23. Sibaji Biswas CFO said the underlying growth at constant currency has been 25% vs. underlying growth reported of 30%. Prakash Agarwal from\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":131845,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133712,"position":1},"title":"Torrent Pharmaceuticals Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 1, 2022","format":false,"excerpt":"Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY23 Earnings Concall Management Update: TORNTPHARM launched four products in 1Q23 and will be launching 4 products in 2Q23, of which three are expected to be day-one launches. Q&A Highlights: Tushar Manudhane of Motilal Oswal asked about shortage of medicine in Germany\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":132138,"url":"https:\/\/alphastreet.com\/india\/piramal-enterprises-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133712,"position":2},"title":"Piramal Enterprises Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 2, 2022","format":false,"excerpt":"https:\/\/youtu.be\/kHUXId_eoxg Key highlights from Piramal Enterprises Ltd (PEL) Q1 FY23 Earnings Concall Management Update: PEL said that it\u2019s on track to completion of de-merger and the listing of Piramal Pharma by 3Q23. Q&A Highlights: Tushar Manudhane from Motilal Oswal asked about the overall pharma revenue guidance for FY23-24. Jairam Sridharan\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":131835,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133712,"position":3},"title":"Sun Pharmaceutical Industries Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 1, 2022","format":false,"excerpt":"Key highlights from Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Management Update: SUNPHARMA recorded the highest ever quarterly revenue in 1Q23, with sales increasing 14% YonY, excluding the contribution of 1Q22. SUNPHARMA\u2019s current generic pipeline for the US includes 89 ANDAs and 13 NDAs awaiting approval with the\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":136169,"url":"https:\/\/alphastreet.com\/india\/cipla-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133712,"position":4},"title":"Cipla Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 9, 2022","format":false,"excerpt":"Key highlights from Cipla Limited (CIPLA) Q2 FY23 Earnings Concall Management Update: [00:02:21] CIPLA reported the highest quarterly revenue historically of INR5,829 crores. Q&A Highlights: [00:18:50] Tushar Manudhane from Motilal Oswal asked about the outlook for 2H23 on the GM front and if there is any revision in the EBITDA\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":140051,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133712,"position":5},"title":"Dr Lal PathLabs Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 3, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:12:28] Dheeresh Pathak from WhiteOak asked about the revenue and EBITDA for Suburban for 3Q23. C. A. Ved Prakash CFO said Suburban had revenue of INR37 crores, with INR35 crores from non-COVID and the rest from\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=133712"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133712\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=133712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=133712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=133712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}